Molecular Profiling Across 82,328 NSCLC Samples for Universal Testing

Biomarker testing underpins targeted therapy in non-small cell lung cancer (NSCLC), enabling use of FDA-approved and emerging therapies. This study leverages large-scale data to characterize the landscape of actionable genomic alterations across NSCLC histologic subtypes and varied clinicodemographic subgroups.

The authors analyzed 82,328+ samples profiled with a single comprehensive genomic profiling (CGP) assay to describe the distribution of actionable alterations and to inform universal molecular testing across NSCLC subtypes. While the abstract emphasizes the value of broad testing to improve access to targeted treatments, it also notes a substantial proportion of advanced NSCLC patients may not currently benefit from precision oncology, highlighting gaps between guidelines and real-world practice.

The study aims to support equitable implementation of molecular testing to ensure all patients with NSCLC have the opportunity to receive genotype-directed therapies. Uncertainty remains regarding the precise prevalence of actionable alterations by histology and subgroup, as well as specific regional or demographic disparities, given that detailed results are not provided in the available content.